November 19, 2024 01:00 AM EST
R&D

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

Max Gelman

Senior Editor

Bio­gen and UCB on Tues­day shared an ex­pand­ed dataset for their Phase 3 lu­pus pro­gram, which they said two months ago suc­ceed­ed in a piv­otal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA of­fers more guid­ance on de­vel­op­ing cell and gene ther­a­pies

Rock­et shares promis­ing long-term re­sults from rare heart dis­ease gene ther­a­py in small study

No­var­tis strikes ra­dio­phar­ma deal with Ra­tio worth up to $745M

A rare neu­ro­log­i­cal dis­ease is Sage’s last, best hope af­ter fail­ures in de­pres­sion

Neu­ro­gene pa­tient had life-threat­en­ing side ef­fect in Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times